Arno Therapeutics Reports Positive Interim Results from Glioblastoma Study; Phase II Enrollment to Continue
June 24, 2011 by
Filed under class registration
Arno Therapeutics Reports Positive Interim Results from Glioblastoma Study; Phase II Enrollment to Continue
Arno Therapeutics, Inc. (OTCBB: ARNI) announced today that its Phase II clinical study of AR-67 has met pre-defined interim goals for patients with …
Read more on Finanzen.net
Teva and CureTech Announce Positive Phase II Data from CT-011, an Investigational Antibody in Diffuse Large B Cell …
May 23, 2011 by
Filed under class registration system
Teva and CureTech Announce Positive Phase II Data from CT-011, an Investigational Antibody in Diffuse Large B Cell …
JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and CureTech, a portfolio company of Teva and Clal Biotechnology Industries announced today preliminary topline results for CT-011, an investigational anti-PD-1 monoclonal antibody. CT-011 met the primary endpoint of improved [...]
Positive data from Gloucester Pharmaceuticals’ ISTODAX study presented at the ASH meeting
December 6, 2009 by
Filed under class registration software
Positive data from Gloucester Pharmaceuticals’ ISTODAX study presented at the ASH meeting
Gloucester Pharmaceuticals announced today the presentation of positive data from an analysis of ISTODAX® (romidepsin) in a subset of patients from Gloucester’s registration study in cutaneous T-cell lymphoma (CTCL) at the 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, [...]